John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.
John Hays, MD, PhD
Advertisement
Articles by John Hays, MD, PhD
John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.
John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.
John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.
John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.
John Hays, MD, PhD, discusses investigational combinations of PARP inhibitors and immunotherapy in ovarian cancer.
John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian CancerDecember 10th 2019
Dr. Hays on Immunotherapy in Ovarian Cancer TreatmentJanuary 14th 2020
Dr. Hays on Immunotherapy Research in Gynecologic CancerFebruary 21st 2020
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
5